CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

Summary

Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3-Way Cross-Over Study To Evaluate The Effect Of A Triple Combination Of Beclometasone Dipropionate And Formoterol Fumarate Plus Glycopyrronium (CHF5993) And A Dual Combination Of Beclometasone Dipropionate Plus Formoterol Fumarate (CHF1535) Both Administered Via pMDI On Lung Hyperinflation And Exercise Endurance Time In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Timeline

Start

2021-10-28

Primary completion

2023-02-24

Completion

2023-02-24

Publications

• Watz H, Kirsten AM, Ludwig-Sengpiel A, Krull M, Mroz RM, Georges G, Varoli G, Charretier R, Cortellini M, Vele A, Galkin D. Effects of inhaled beclometasone dipropionate/formoterol fumarate/glycopyrronium vs. beclometasone dipropionate/formoterol fumarate and placebo on lung hyperinflation and exercise endurance in chronic obstructive pulmonary disease: a randomised controlled trial. Respir Res. 2024 Oct 17;25(1):378. doi: 10.1186/s12931-024-02993-x.

Drugs

Indications